GSA Capital Partners LLP bought a new stake in Syndax Pharmaceuticals Inc (NASDAQ:SNDX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 52,400 shares of the company’s stock, valued at approximately $368,000. GSA Capital Partners LLP owned approximately 0.21% of Syndax Pharmaceuticals at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in SNDX. Los Angeles Capital Management & Equity Research Inc. grew its position in shares of Syndax Pharmaceuticals by 433.3% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 70,140 shares of the company’s stock valued at $492,000 after acquiring an additional 56,988 shares during the period. JPMorgan Chase & Co. grew its position in shares of Syndax Pharmaceuticals by 5.3% in the 1st quarter. JPMorgan Chase & Co. now owns 426,941 shares of the company’s stock valued at $6,075,000 after acquiring an additional 21,581 shares during the period. Opaleye Management Inc. bought a new position in shares of Syndax Pharmaceuticals in the 1st quarter valued at about $3,166,000. Point72 Asset Management L.P. bought a new position in shares of Syndax Pharmaceuticals in the 1st quarter valued at about $4,269,000. Finally, Spark Investment Management LLC bought a new position in shares of Syndax Pharmaceuticals in the 2nd quarter valued at about $198,000. 64.20% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ SNDX traded down $0.17 during mid-day trading on Friday, reaching $6.39. 210,442 shares of the company were exchanged, compared to its average volume of 352,972. The stock has a market cap of $188.71 million, a PE ratio of -2.20 and a beta of 1.27. Syndax Pharmaceuticals Inc has a twelve month low of $6.10 and a twelve month high of $15.20.
Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, August 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.13. Syndax Pharmaceuticals had a negative net margin of 3,190.51% and a negative return on equity of 80.35%. The company had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $0.38 million. On average, equities analysts anticipate that Syndax Pharmaceuticals Inc will post -3.12 EPS for the current fiscal year.
SNDX has been the subject of a number of analyst reports. HC Wainwright initiated coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, July 12th. They issued a “buy” rating and a $30.00 price objective for the company. Citigroup decreased their price objective on shares of Syndax Pharmaceuticals from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday. Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, ValuEngine upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, July 6th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Syndax Pharmaceuticals has a consensus rating of “Buy” and an average target price of $23.20.
Syndax Pharmaceuticals Profile
Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.
Recommended Story: What Factors Can Affect Return on Equity?
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.